En Es
Categories

Industry News

Hologic Receives FDA Clearance for Genius AI Detection Technology for Early Breast Cancer Detection

By HospiMedica International staff writers
02 Dec 2020

Image: The Genius AI Detection software (Photo courtesy of Hologic, Inc.)Hologic, Inc. (Marlborough, MA, USA) has received US Food and Drug Administration (FDA) clearance for its Genius AI Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.

The new technology which Hologic has now made commercially available represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius 3D Mammography exam. The new technology highlights areas with subtle potential cancers that can be difficult to detect for further examination by the radiologist, and is designed to provide higher sensitivity and a false-positive rate much lower than Hologic’s previous generation CAD products.

The new software delivers key metrics at the time of image acquisition to help radiologists categorize and prioritize cases by complexity and expected read time in order to optimize workflow and expedite patient care. It is the only deep learning product on the market that runs on the acquisition workstation of the mammography system without the need for a separate server, providing a simple, convenient and secure environment. The Genius AI Detection software is the only 3D CAD solution that supports Hologic’s latest innovations in tomosynthesis imaging, Clarity HD and 3DQuorum imaging technology, in addition to standard-resolution tomosynthesis.

“As the latest breakthrough in breast cancer screening, Genius AI Detection reinforces Hologic’s commitment to improving cancer detection, optimizing workflow and enhancing the patient experience across every step of the breast health care continuum,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “Not only did studies show that Genius AI Detection aids in image interpretation by highlighting suspicious, and often subtle, areas of interest, it also provides the radiologist the opportunity to prioritize the most concerning patient cases. This is a real game changer as it has the potential to shorten the cycle between screening and diagnostic follow-up, and ultimately improve patient outcomes.”





E-mail Print
FaceBook Twitter Google+ Linked in

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of human diseases, such as tuberculosis, strep throat, pneumonia, and sexually transmitted diseases, as well as for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) contamination of blood
More info

More articles about Hologic

20 Oct 2021
Hologic Acquires Bolder Surgical to Expand Surgical Franchise
Hologic, Inc. (Marlborough, MA, USA) is set to acquire Bolder Surgical (Louisville, CO, USA; www.boldersurgical.com), a provider of advanced energy vessel sealing surgical devices, in a deal that will expand its surgical franchise.
Read More
24 Jun 2021
Hologic Completes Acquisition of Mobidiag
Hologic, Inc. (Marlborough, MA, USA) has completed its previously announced acquisition of Mobidiag Ltd. (Espoo, Finland), an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately USD 808 million.
Read More
02 Mar 2021
Hologic Acquires European Molecular Diagnostic Company Diagenode
Hologic, Inc. (Marlborough, MA, USA) has acquired Diagenode (Liège, Belgium), a developer and manufacturer of molecular diagnostic assays and epigenetics products, which is expected to diversify its diagnostic business across test menu, customer segments and geography.
Read More
04 Feb 2021
Hologic Partners with Google Cloud to Focus on AI and Machine Learning for Advancing Digital Diagnostic Capabilities
Hologic, Inc. (Marlborough, MA, USA) and Google Cloud have entered into a new agreement to focus on enhancing artificial intelligence (AI) and machine learning (ML) to bring about breakthrough results in cervical cancer screening.
Read More
07 Jan 2021
Hologic to Acquire Diagnostic Tests Provider Biotheranostics
Hologic, Inc. (Marlborough, MA, USA) has agreed to acquire Biotheranostics, Inc. (San Diego, CA, USA), a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately USD 230 million.
Read More
05 Jan 2021
Hologic Acquires SOMATEX Medical Technologies
Hologic, Inc. (Marlborough, MA, USA) has completed the acquisition of SOMATEX Medical Technologies GmbH (Berlin, Germany), a leader in biopsy site markers and localization technologies, for approximately USD 64 million.
Read More
20 Aug 2020
Hologic Showcased Latest Advances at Virtual ECR Congress 2020
Hologic, Inc. (Marlborough, MA, USA) showcased its latest advances and shared its new innovations on its virtual booth at the online ECR 2020 event held on July 15-21.
Read More
15 Dec 2016
Hologic to Sell Blood-Screening Business to Grifols for USD 1.85 Billion
US medical device maker Hologic, Inc. has agreed to sell off its share of the Procleix blood-screening business to long-time partner, Grifols SA, for USD 1.85 billion in cash.
Read More

Additional news

27 Sep 2022
Mindray Showcases Hematology Innovations at ISLH 2022
Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations in Laboratory Hematology (ISLH 2022) held between September 8-10 in Bologna, Italy.
Read More
23 Sep 2022
Parker Labs Partners with Tristel to Deliver Ultrasound Disinfectant for U.S. Market
Parker Laboratories Inc. (Fairfield, NJ, USA) has entered a commercial partnership with Tristel plc (Newmarket, UK) to manufacture and distribute the company's disinfectant foams for U.S. markets.
Read More
19 Sep 2022
Pluslife and FIND Set Collaborate to Empower LMICs with Next-Gen POC Molecular Testing in Women’s Healthcare
Guangzhou Pluslife Biotechnology (Pluslife, Guangzhou, China) and the Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) have entered into a strategic collaboration to support low- and middle-income countries (LMICs) in the development of diagnostic tools for women’s healthcare by providing access to next generation point of care (POC) molecular testing technology.
Read More
19 Sep 2022
RSNA 2022 to Showcase Latest Technologies for Advancing Patient Care
The Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) has announced Technical Exhibits highlights for their 108th Scientific Assembly and Annual Meeting (RSNA 2022) held in Chicago at McCormick Place, Nov. 27 – Dec. 1.
Read More
16 Sep 2022
International Hospital Federation Awards 2022 Finalists Announced
The International Hospital Federation (IHF; Geneva, Switzerland) has announced the finalists of the IHF Awards 2022 after scoring entries in seven categories.
Read More
16 Sep 2022
Intelerad Acquires Life Image to Create World’s Largest Medical Image Exchange Network
Intelerad Medical Systems (Raleigh, NC, USA), a leading global provider of enterprise imaging solutions, has acquired Life Image (Newton, MA, USA), one of the largest image exchange networks of curated clinical and imaging data, creating the largest medical image exchange network in the world and laying the groundwork for the elimination of costly CDs as the primary means of image transfer.
Read More
13 Sep 2022
Global Diagnostic Labs Market Driven by Increased POCT Testing and Smart Portable Devices
The global diagnostic labs market is projected grow at a CAGR of 8.3% from over USD 297 billion in 2021 to more than USD 514 billion by 2028, driven by the increasing prevalence of chronic diseases, growing use of POC diagnostics, and rising healthcare expenditures.
Read More
12 Sep 2022
ECR 2023 Now Set to Take Place from 1-5 March in Vienna
The European Society of Radiology (ESR, Vienna, Austria) has announced that the European Congress of Radiology (ECR) 2023 will now take place on March 1-5, 2023 in Vienna.
Read More
09 Sep 2022
Global PCR and Real-Time PCR Testing Market Driven by Need for Early Disease Detection
The global PCR and real time PCR testing market is expected to grow at a CAGR of 6.2% from USD 18.5 billion in 2021 to USD 19.64 billion in 2022 and further grow to USD 24.61 billion in 2026 at a CAGR of 5.8%.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions